Ocrelizumab vs Ofatumumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: CD20 · full Multiple Sclerosis pipeline

Ocrelizumab

Marketed by Roche

Approved in Multiple Sclerosismonoclonal antibody
Partial signal

NCT00676715 · Phase 2 · completed

Randomized, double-blind phase 2 in relapsing-remitting multiple sclerosis (220 participants). Both ocrelizumab doses reduced gadolinium-enhancing brain lesions decisively versus placebo (p<0.0001); the endpoint is an MRI biomarker rather than a clinical relapse or disability outcome, which is why the grade is moderate despite the clear result.

Next expected readout: December 2026 · NCT04466150 (registry estimate)

Reported efficacy

Protocol-defined Annualized Relapse Rate (ARR) (Up to after the last participant randomized completed 24 weeks since first study treatment administration (up to approximately 160 weeks)): Protocol-defined annualized relapse rate: ocrelizumab 0.070 vs fingolimod 0.135; adjusted rate ratio 0.517 (95% CI 0.193 to 1.329), non-inferiority analysis (CT.gov posted results); Roche states non-inferiority to fingolimod with a 48% lower relapse risk. (met)

Result source: NCT05123703

Ofatumumab

Marketed by Novartis and partners

Approved in Multiple Sclerosismonoclonal antibody
Reliable signal

NCT02792231 · Phase 3 · completed

This was a large, randomized, quadruple-blind, active-controlled trial of 955 participants, comparing ofatumumab with teriflunomide. The prespecified primary clinical endpoint, annualized confirmed relapse rate, was significantly better with ofatumumab (p<0.001), supporting a strong evidence grade despite mixed findings for some secondary measures.

Next expected readout: April 2027 · NCT05090371 (registry estimate)

Reported efficacy

Annualized Relapse Rate (ARR) (Baseline up to 2.5 years): Annualized Relapse Rate (ASCLEPIOS II): 0.10 (ofatumumab) vs 0.25 (teriflunomide); difference -0.15 (95% CI: -0.20, -0.09) (met)

Result source: NCT02792231

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOcrelizumabOfatumumab
Annualised relapse rate0.2 vs 0.3vs Interferon Beta-1awk 96 · n 410NCT01247324
3 other results
  • 0.2 vs 0.3 wk 96 · n 417 · Phase 3 · primary NCT01412333
  • 0.1 vs 0.6 600 mg / 600 mg · wk 24 · n 55 · Phase 2 · secondary NCT00676715
  • 0.2 vs 0.6 1000 mg / 600 mg · wk 24 · n 55 · Phase 2 · secondary NCT00676715
0.1 vs 0.3vs TER20 mg · n 469NCT02792231
4 other results
  • 0.1 vs 0.2 20 mg · n 454 · Phase 3 · primary NCT02792218
  • 0.1 vs 0.2 20 mg · n 461 · Phase 3 · secondary NCT02792231
  • 0.1 vs 0.2 20 mg · n 453 · Phase 3 · secondary NCT02792218
  • 0.3 vs 0.6 20 mg · wk 24 · n 43 · Phase 2 · secondary NCT03249714
Free of 3-month confirmed disability progression (%)—Trial running · NCT05834855—Not posted · NCT04788615
New or enlarging T2 lesions430 vs 1916vs Interferon Beta-1awk 96 · n 410NCT01247324
1 other result
  • 380 vs 2103 wk 96 · n 417 · Phase 3 · secondary NCT01412333
—Not posted · NCT04788615

Annualised relapse rate

Ocrelizumab
0.2 vs 0.3vs Interferon Beta-1awk 96 · n 410NCT01247324
3 other results
  • 0.2 vs 0.3 wk 96 · n 417 · Phase 3 · primary NCT01412333
  • 0.1 vs 0.6 600 mg / 600 mg · wk 24 · n 55 · Phase 2 · secondary NCT00676715
  • 0.2 vs 0.6 1000 mg / 600 mg · wk 24 · n 55 · Phase 2 · secondary NCT00676715
Ofatumumab
0.1 vs 0.3vs TER20 mg · n 469NCT02792231
4 other results
  • 0.1 vs 0.2 20 mg · n 454 · Phase 3 · primary NCT02792218
  • 0.1 vs 0.2 20 mg · n 461 · Phase 3 · secondary NCT02792231
  • 0.1 vs 0.2 20 mg · n 453 · Phase 3 · secondary NCT02792218
  • 0.3 vs 0.6 20 mg · wk 24 · n 43 · Phase 2 · secondary NCT03249714

Free of 3-month confirmed disability progression (%)

Ocrelizumab
—Trial running · NCT05834855
Ofatumumab
—Not posted · NCT04788615

New or enlarging T2 lesions

Ocrelizumab
430 vs 1916vs Interferon Beta-1awk 96 · n 410NCT01247324
1 other result
  • 380 vs 2103 wk 96 · n 417 · Phase 3 · secondary NCT01412333
Ofatumumab
—Not posted · NCT04788615
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. Ocrelizumab: 10 of 10 rows · Ofatumumab: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOcrelizumab
Rows use multiple source trials
Ofatumumab
Rows use multiple source trials
Annualized Relapse
event rate · per year
No placebo or comparator arm
0.03 per year @ 96wka,b,c
NCT02861014 · Phase 3 · registry result, not featured evidence
1 other source trial
0.046 per year @ 96wk
NCT02637856 · Phase 3 · registry result, not featured evidence
0.06 per yeara,b,c
NCT04353492 · Phase 3 · registry result, not featured evidence
MRI-T2 Lesion Volume
percent change · % of baseline
-3.366% (n=464) vs 7.426% (n=234) placebo @ 120wk600 mga,b,d
NCT01194570 · Phase 3
-2.6% (n=447) vs 17.8% (n=437) TER @ 104wk20 mga,b,d
NCT02792231 · Phase 3
1 other source trial
-2.6% (n=436) vs 13.5% (n=430) TER @ 104wk20 mg
NCT02792218 · Phase 3
NEDA
responder rate · % of participants
47.4% (n=289) vs 27.1% (n=291) Interferon Beta-1a @ 96wka,b,e
NCT01247324 · Phase 3
1 other source trial
43.9% (n=289) vs 24.1% (n=270) Interferon Beta-1a @ 96wk
NCT01412333 · Phase 3 · registry result, not featured evidence
9.8% (n=433) vs 5.1% (n=427) TER @ 104wk20 mga,b,e
NCT02792231 · Phase 3
1 other source trial
14.4% (n=428) vs 3.2% (n=413) TER @ 104wk20 mg
NCT02792218 · Phase 3
NEDA
responder rate · % of participants
No placebo or comparator arm
74.8% (n=658) @ 96wkf,a,b,c
NCT02861014 · Phase 3 · registry result, not featured evidence
81.1% (n=95)f,a,b,c
NCT05084638 · Phase 4 · registry result, not featured evidence
Sustained Reduction of Disability
responder rate · % of participants
20% (n=310) vs 12.42% (n=306) Interferon Beta-1a @ 96wka,b,e
NCT01247324 · Phase 3
1 other source trial
21.38% (n=318) vs 18.83% (n=308) Interferon Beta-1a @ 96wk
NCT01412333 · Phase 3 · registry result, not featured evidence
11% (n=749) vs 8.2% (n=724) TER @ 104wk20 mgg,a,b,e
NCT02792231 · Phase 3
show 2 more doses
12.3% (n=374) vs 8.1% (n=361) TER @ 104wk20 mg
NCT02792231 · Phase 3
5.8% (n=749) vs 4.6% (n=724) TER @ 104wk20 mg
NCT02792231 · Phase 3
T2 Lesion Volume
absolute change · mL
No placebo or comparator arm
-558.6 mL @ 96wkf,a,b,h
NCT02861014 · Phase 3 · registry result, not featured evidence
-0.32 mL @ 52wkf,a,b,h
NCT05199571 · Phase 4 · registry result, not featured evidence
Dropout rate
16.4%600 mg / 600 mgi
NCT00676715 · Phase 2
show 25 more results
—600 mg
NCT00676715 · Phase 2
—600 mg / 600 mg
NCT00676715 · Phase 2
21.8%1000 mg / 600 mg
NCT00676715 · Phase 2
—1000 mg / 600 mg
NCT00676715 · Phase 2
55.3%600 mg
NCT01194570 · Phase 3
—DB OCRELIZUMAB
NCT01194570 · Phase 3
—OLE OCRELIZUMAB
NCT01194570 · Phase 3
—OLE PLACEBO
NCT01194570 · Phase 3
41.7%Ocrelizumab
NCT01247324 · Phase 3
—Ocrelizumab + Placebo (Double Blin
NCT01247324 · Phase 3
—Ocrelizumab + Placebo (Open Label
NCT01247324 · Phase 3
7.7%
NCT04998851 · Phase 4 · registry result, not featured evidence
0%
NCT04261790 · Phase 4 · registry result, not featured evidence
10%
NCT03853746 · Phase 4 · registry result, not featured evidence
96.8%PPMS Cohort: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
100%RMS Cohort Arm 1: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
100%RMS Cohort Arm 2: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
100%RMS Cohort Arm 3: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
100%RMS Cohort Arm 4: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
—Ocrelizumab + Interferon Beta-1a P
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
—Ocrelizumab + Interferon Beta-1a P
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
5.7%
NCT02861014 · Phase 3 · registry result, not featured evidence
36%Ocrelizumab
NCT02637856 · Phase 3 · registry result, not featured evidence
—Ocrelizumab (Substudy)
NCT02637856 · Phase 3 · registry result, not featured evidence
7%
NCT02980042 · Phase 3 · registry result, not featured evidence
17%20 mgi
NCT02792231 · Phase 3
show 26 more results
—20mg
NCT02792231 · Phase 3
10.5%20 mg
NCT02792218 · Phase 3
—20 mg
NCT02792218 · Phase 3
19.8%20 mg
NCT04486716 · Phase 3
2.9%60 mg q12w
NCT01457924 · Phase 2
9.4%60 mg q4w
NCT01457924 · Phase 2
6.3%30 mg q12w
NCT01457924 · Phase 2
14.7%3 mg q12w
NCT01457924 · Phase 2
0%700 mg
NCT00640328 · Phase 2 · monotherapy
9.1%300 mg
NCT00640328 · Phase 2 · monotherapy
0%100 mg
NCT00640328 · Phase 2 · monotherapy
7.6%Ofatumumab
NCT05084638 · Phase 4 · registry result, not featured evidence
—Ofatumumab-Treated
NCT05084638 · Phase 4 · registry result, not featured evidence
4%
NCT05199571 · Phase 4 · registry result, not featured evidence
—20 mg
NCT04353492 · Phase 3 · registry result, not featured evidence
6.9%Ofatumumab
NCT04353492 · Phase 3 · registry result, not featured evidence
7%20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0.8%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
5.5%600 mg / 600 mgi
NCT00676715 · Phase 2
show 25 more results
—600 mg
NCT00676715 · Phase 2
—600 mg / 600 mg
NCT00676715 · Phase 2
3.6%1000 mg / 600 mg
NCT00676715 · Phase 2
—1000 mg / 600 mg
NCT00676715 · Phase 2
8.2%600 mg
NCT01194570 · Phase 3
—DB OCRELIZUMAB
NCT01194570 · Phase 3
—OLE OCRELIZUMAB
NCT01194570 · Phase 3
—OLE PLACEBO
NCT01194570 · Phase 3
8.5%Ocrelizumab
NCT01247324 · Phase 3
—Ocrelizumab + Placebo (Double Blin
NCT01247324 · Phase 3
—Ocrelizumab + Placebo (Open Label
NCT01247324 · Phase 3
—
NCT04998851 · Phase 4 · registry result, not featured evidence
—
NCT04261790 · Phase 4 · registry result, not featured evidence
—
NCT03853746 · Phase 4 · registry result, not featured evidence
0%PPMS Cohort: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
4.3%RMS Cohort Arm 1: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
6.5%RMS Cohort Arm 2: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
7.1%RMS Cohort Arm 3: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
0%RMS Cohort Arm 4: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
—Ocrelizumab + Interferon Beta-1a P
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
—Ocrelizumab + Interferon Beta-1a P
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
1%
NCT02861014 · Phase 3 · registry result, not featured evidence
1.5%Ocrelizumab
NCT02637856 · Phase 3 · registry result, not featured evidence
—Ocrelizumab (Substudy)
NCT02637856 · Phase 3 · registry result, not featured evidence
—
NCT02980042 · Phase 3 · registry result, not featured evidence
3.1%20 mgi
NCT02792231 · Phase 3
show 26 more results
—20mg
NCT02792231 · Phase 3
3.2%20 mg
NCT02792218 · Phase 3
—20 mg
NCT02792218 · Phase 3
4.5%20 mg
NCT04486716 · Phase 3
0%60 mg q12w
NCT01457924 · Phase 2
3.1%60 mg q4w
NCT01457924 · Phase 2
3.1%30 mg q12w
NCT01457924 · Phase 2
11.8%3 mg q12w
NCT01457924 · Phase 2
0%700 mg
NCT00640328 · Phase 2 · monotherapy
9.1%300 mg
NCT00640328 · Phase 2 · monotherapy
0%100 mg
NCT00640328 · Phase 2 · monotherapy
—Ofatumumab
NCT05084638 · Phase 4 · registry result, not featured evidence
—Ofatumumab-Treated
NCT05084638 · Phase 4 · registry result, not featured evidence
—
NCT05199571 · Phase 4 · registry result, not featured evidence
—20 mg
NCT04353492 · Phase 3 · registry result, not featured evidence
0.5%Ofatumumab
NCT04353492 · Phase 3 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0.8%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
Serious AEs
—600 mg / 600 mgi
NCT00676715 · Phase 2
show 25 more results
27.2%600 mg
NCT00676715 · Phase 2
30.9%600 mg / 600 mg
NCT00676715 · Phase 2
—1000 mg / 600 mg
NCT00676715 · Phase 2
29.1%1000 mg / 600 mg
NCT00676715 · Phase 2
—600 mg
NCT01194570 · Phase 3
21.4%DB OCRELIZUMAB
NCT01194570 · Phase 3
45.3%OLE OCRELIZUMAB
NCT01194570 · Phase 3
37.3%OLE PLACEBO
NCT01194570 · Phase 3
—Ocrelizumab
NCT01247324 · Phase 3
6.9%Ocrelizumab + Placebo (Double Blin
NCT01247324 · Phase 3
33%Ocrelizumab + Placebo (Open Label
NCT01247324 · Phase 3
0%
NCT04998851 · Phase 4 · registry result, not featured evidence
0%
NCT04261790 · Phase 4 · registry result, not featured evidence
0%
NCT03853746 · Phase 4 · registry result, not featured evidence
29%PPMS Cohort: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
21.7%RMS Cohort Arm 1: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
16.1%RMS Cohort Arm 2: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
3.6%RMS Cohort Arm 3: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
27.8%RMS Cohort Arm 4: Ocrelizumab + LP
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
7%Ocrelizumab + Interferon Beta-1a P
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
34.6%Ocrelizumab + Interferon Beta-1a P
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
7.2%
NCT02861014 · Phase 3 · registry result, not featured evidence
7.7%Ocrelizumab
NCT02637856 · Phase 3 · registry result, not featured evidence
1.6%Ocrelizumab (Substudy)
NCT02637856 · Phase 3 · registry result, not featured evidence
8%
NCT02980042 · Phase 3 · registry result, not featured evidence
—20 mgi
NCT02792231 · Phase 3
show 26 more results
8.7%20mg
NCT02792231 · Phase 3
—20 mg
NCT02792218 · Phase 3
11%20 mg
NCT02792218 · Phase 3
5.9%20 mg
NCT04486716 · Phase 3
2.9%60 mg q12w
NCT01457924 · Phase 2
6.3%60 mg q4w
NCT01457924 · Phase 2
0%30 mg q12w
NCT01457924 · Phase 2
2.9%3 mg q12w
NCT01457924 · Phase 2
0%700 mg
NCT00640328 · Phase 2 · monotherapy
18.2%300 mg
NCT00640328 · Phase 2 · monotherapy
0%100 mg
NCT00640328 · Phase 2 · monotherapy
—Ofatumumab
NCT05084638 · Phase 4 · registry result, not featured evidence
6.7%Ofatumumab-Treated
NCT05084638 · Phase 4 · registry result, not featured evidence
0%
NCT05199571 · Phase 4 · registry result, not featured evidence
6%20 mg
NCT04353492 · Phase 3 · registry result, not featured evidence
—Ofatumumab
NCT04353492 · Phase 3 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
2.5%20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
2.3%20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
1.6%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
3.1%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
600 mgi
multiple sclerosis relapse 27.2% (placebo 48.1%)
covid-19 25.2% (placebo 22.2%)
infusion related reaction 22.3% (placebo 53.7%)
NCT00676715 · Phase 2
show 21 more results
600 mg / 600 mg
infusion related reaction 45.5% (placebo 53.7%)
multiple sclerosis relapse 34.5% (placebo 48.1%)
nasopharyngitis 27.3% (placebo 18.5%)
NCT00676715 · Phase 2
1000 mg / 600 mg
infusion related reaction 52.7% (placebo 53.7%)
multiple sclerosis relapse 38.2% (placebo 48.1%)
urinary tract infection 27.3% (placebo 25.9%)
NCT00676715 · Phase 2
infusion related reaction 39.9% (placebo 25.5%)
nasopharyngitis 24.1% (placebo 26.4%)
urinary tract infection 21.2% (placebo 23.8%)
NCT01194570 · Phase 3
urinary tract infection 34.4% (placebo 23.8%)
nasopharyngitis 27.1% (placebo 26.4%)
covid-19 20.6% (placebo 0%)
NCT01194570 · Phase 3
nasopharyngitis 30.4% (placebo 26.4%)
urinary tract infection 27.8% (placebo 23.8%)
infusion related reaction 25.3% (placebo 25.5%)
NCT01194570 · Phase 3
infusion related reaction 30.9%
upper respiratory tract infection 14.5%
urinary tract infection 12.7%
NCT01247324 · Phase 3
urinary tract infection 28.7%
covid-19 27.3%
upper respiratory tract infection 25.6%
NCT01247324 · Phase 3
covid-19 46.2%
infusion related reaction 23.1%
nasopharyngitis 23.1%
NCT04998851 · Phase 4 · registry result, not featured evidence
headache 30%
cough 20%
blood pressure fluctuation 10%
NCT04261790 · Phase 4 · registry result, not featured evidence
bronchitis 11.1%
congestion 11.1%
cough 11.1%
NCT03853746 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 41.9%
infusion related reaction 38.7%
arthralgia 35.5%
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
infusion related reaction 65.2%
upper respiratory tract infection 30.4%
covid-19 17.4%
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
sinusitis 32.3%
infusion related reaction 29%
headache 19.4%
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
infusion related reaction 57.1%
upper respiratory tract infection 35.7%
pain in extremity 17.9%
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 66.7%
infusion related reaction 61.1%
urinary tract infection 38.9%
NCT02688985 · Phase 3 · registry result, not featured evidence · combination
infusion related reaction 37.9%
nasopharyngitis 19.2%
upper respiratory tract infection 15.6%
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 30.6%
covid-19 27.4%
nasopharyngitis 27.4%
NCT01412333 · Phase 3 · registry result, not featured evidence · combination
infusion related reaction 43.2%
nasopharyngitis 30.9%
headache 22.6%
NCT02861014 · Phase 3 · registry result, not featured evidence
infusion related reaction 43.3%
urinary tract infection 14.5%
nasopharyngitis 10.5%
NCT02637856 · Phase 3 · registry result, not featured evidence
infusion related reaction 12.4%
fatigue 0%
headache 0%
NCT02637856 · Phase 3 · registry result, not featured evidence
upper respiratory infection 36%
headache 14%
nausea 14%
NCT02980042 · Phase 3 · registry result, not featured evidence
20mgi
injection related reaction 24.7%
injection related reaction 24.7%
nasopharyngitis 18.3%
NCT02792231 · Phase 3
show 18 more results
20 mg
nasopharyngitis 17.6%
injection related reaction 15.9%
headache 12.7%
NCT02792218 · Phase 3
20 mg
covid-19 30.4%
fatigue 11.8%
headache 11.8%
NCT04486716 · Phase 3
60 mg q12w
injection related reaction 50%
nasopharyngitis 20.6%
fatigue 5.9%
NCT01457924 · Phase 2
60 mg q4w
injection related reaction 65.6%
nasopharyngitis 10.9%
headache 9.4%
NCT01457924 · Phase 2
30 mg q12w
injection related reaction 40.6%
nasopharyngitis 12.5%
fatigue 9.4%
NCT01457924 · Phase 2
3 mg q12w
injection related reaction 47.1%
urinary tract infection 8.8%
anaemia 5.9%
NCT01457924 · Phase 2
700 mg
rash 57.1% (placebo 50%)
throat irritation 28.6% (placebo 0%)
upper respiratory tract infection 28.6% (placebo 75%)
NCT00640328 · Phase 2 · monotherapy
300 mg
throat irritation 36.4% (placebo 0%)
rash 27.3% (placebo 50%)
viral infection 27.3% (placebo 0%)
NCT00640328 · Phase 2 · monotherapy
100 mg
nasopharyngitis 50% (placebo 25%)
throat irritation 37.5% (placebo 0%)
depression 25% (placebo 0%)
NCT00640328 · Phase 2 · monotherapy
chills 36.1%
headache 27.7%
myalgia 26.1%
NCT05084638 · Phase 4 · registry result, not featured evidence
injection related reaction 43.4%
covid-19 12.1%
upper respiratory tract infection 12.1%
NCT05199571 · Phase 4 · registry result, not featured evidence
20 mg
injection related reaction 53.4%
covid-19 37%
nasopharyngitis 17.1%
NCT04353492 · Phase 3 · registry result, not featured evidence
20 mg
nasopharyngitis 17.5% (placebo 19%)
rash 7.5% (placebo 0%)
alanine aminotransferase increased 5% (placebo 4.8%)
NCT03249714 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 20.9% (placebo 19%)
nasopharyngitis 14% (placebo 19%)
oral herpes 9.3% (placebo 0%)
NCT03249714 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 32%
headache 10.2%
injection site reaction 8.6%
NCT03560739 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 38.5%
diarrhoea 7.7%
fatigue 7.7%
NCT03560739 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 46.2%
asthenia 7.7%
cough 7.7%
NCT03560739 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 22.3%
injection site reaction 13.1%
headache 5.4%
NCT03560739 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dAssessment timepoints differ: 104 weeks versus 120 weeks.
  5. eAssessment timepoints differ: 104 weeks versus 96 weeks.
  6. fTrial phases differ: Phase 4 versus Phase 3.
  7. gThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  8. hAssessment timepoints differ: 52 weeks versus 96 weeks.
  9. iPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ocrelizumab

Gd-enhancing T1 Lesion 0.6 vs 5.6 placebo lesions @ 24wk600 mg / 600 mg
event count · lesions
NCT00676715 · Phase 2
show 3 more results
2.5 vs 8.7 placebo lesions @ 24wk600 mg / 600 mg
NCT00676715 · Phase 2
0.2 vs 5.6 placebo lesions @ 24wk1000 mg / 600 mg
NCT00676715 · Phase 2
1.8 vs 8.7 placebo lesions @ 24wk1000 mg / 600 mg
NCT00676715 · Phase 2
Relapse Free 85.5% (n=55) vs 75.9% (n=54) placebo @ 24wk600 mg / 600 mg
responder rate · % of participants
NCT00676715 · Phase 2
show 1 more result
87.3% (n=55) vs 75.9% (n=54) placebo @ 24wk1000 mg / 600 mg
NCT00676715 · Phase 2
T2 Lesion Volume -878.84 vs -112.31 placebo mm @ 24wk600 mg / 600 mg
absolute change · mm
NCT00676715 · Phase 2
show 1 more result
-600.89 vs -112.31 placebo mm @ 24wk1000 mg / 600 mg
NCT00676715 · Phase 2
New Gadolinium-Enhancing T1 Lesion 0.8 vs 5.1 placebo lesions @ 24wk600 mg / 600 mg
event count · lesions
NCT00676715 · Phase 2
show 1 more result
0.8 vs 5.1 placebo lesions @ 24wk1000 mg / 600 mg
NCT00676715 · Phase 2
Time to 3m Confirmed Disability Worsening NA vs NA placebo months600 mg
time to event · months
NCT01194570 · Phase 3
show 2 more results
NA vs NA Interferon Beta-1a months @ 108wk
NCT01247324 · Phase 3
NA vs NA Interferon Beta-1a months @ 104wk
NCT01412333 · Phase 3 · registry result, not featured evidence
Time to 6m Confirmed Disability Worsening NA vs NA placebo months600 mg
time to event · months
NCT01194570 · Phase 3
T25-FW 38.933% (n=473) vs 55.097% (n=239) placebo @ 120wk600 mg
percent change · % of baseline
NCT01194570 · Phase 3
Whole Brain Volume -0.902% (n=407) vs -1.093% (n=203) placebo @ 120wk600 mg
percent change · % of baseline
NCT01194570 · Phase 3
SF-36 PCS -0.731 vs -1.108 placebo score @ 120wk600 mg
absolute change · score
NCT01194570 · Phase 3
T1 Gadolinium Enhancing Lesion 21 vs 337 Interferon Beta-1a lesions @ 96wk
event count · lesions
NCT01247324 · Phase 3
New or Enlarging T2 Lesion 430 vs 1916 Interferon Beta-1a lesions @ 96wk
event count · lesions
NCT01247324 · Phase 3
show 1 more result
380 vs 2103 Interferon Beta-1a lesions @ 96wk
NCT01412333 · Phase 3 · registry result, not featured evidence
Time to CDP 6mo NA vs NA Interferon Beta-1a months @ 108wk
time to event · months
NCT01247324 · Phase 3
show 1 more result
NA vs NA Interferon Beta-1a months @ 104wk
NCT01412333 · Phase 3 · registry result, not featured evidence

+ 35 further endpoints in the CSV export.

Ofatumumab

Confirmed Disability Progression 9.4% (n=944) vs 13.5% (n=932) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 17 more results
10.9% (n=944) vs 15% (n=932) TER @ 104wk20 mg
NCT02792231 · Phase 3
9.3% (n=479) vs 13.2% (n=473) TER @ 78wk20 mg
NCT02792231 · Phase 3
10.5% (n=479) vs 14.6% (n=473) TER @ 104wk20 mg
NCT02792231 · Phase 3
9.4% (n=944) vs 13.5% (n=932) TER @ 78wk20 mg
NCT02792231 · Phase 3
10.9% (n=944) vs 15% (n=932) TER @ 104wk20 mg
NCT02792231 · Phase 3
9.4% (n=944) vs 13.5% (n=932) TER @ 78wk20 mg
NCT02792218 · Phase 3
10.9% (n=944) vs 15% (n=932) TER @ 104wk20 mg
NCT02792218 · Phase 3
9.4% (n=465) vs 13.9% (n=459) TER @ 78wk20 mg
NCT02792218 · Phase 3
11.3% (n=465) vs 15.4% (n=459) TER @ 104wk20 mg
NCT02792218 · Phase 3
7.8% (n=944) vs 10.7% (n=932) TER @ 78wk20 mg
NCT02792218 · Phase 3
8.1% (n=944) vs 12% (n=932) TER @ 104wk20 mg
NCT02792218 · Phase 3
7.5% (n=465) vs 11.5% (n=459) TER @ 78wk20 mg
NCT02792218 · Phase 3
8.2% (n=465) vs 13% (n=459) TER @ 104wk20 mg
NCT02792218 · Phase 3
9.4% (n=944) vs 13.5% (n=932) TER @ 78wk20 mg
NCT02792218 · Phase 3
10.9% (n=944) vs 15% (n=932) TER @ 104wk20 mg
NCT02792218 · Phase 3
7.8% (n=944) vs 10.7% (n=932) TER @ 78wk20 mg
NCT02792218 · Phase 3
8.1% (n=944) vs 12% (n=932) TER @ 104wk20 mg
NCT02792218 · Phase 3
Sustained Disability Progression 7.8% (n=944) vs 10.7% (n=932) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 5 more results
8.1% (n=944) vs 12% (n=932) TER @ 104wk20 mg
NCT02792231 · Phase 3
8% (n=479) vs 10% (n=473) TER @ 78wk20 mg
NCT02792231 · Phase 3
8% (n=479) vs 10.9% (n=473) TER @ 104wk20 mg
NCT02792231 · Phase 3
7.8% (n=944) vs 10.7% (n=932) TER @ 78wk20 mg
NCT02792231 · Phase 3
8.1% (n=944) vs 12% (n=932) TER @ 104wk20 mg
NCT02792231 · Phase 3
T1 Gadolinium Enhancing Lesion 0.0317 vs 0.5172 TER per scan20 mg
event count · per scan
NCT02792231 · Phase 3
show 1 more result
0.067 vs 1.0413 placebo per scan @ 24wk20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
Annualized New or Enlarging T2 Lesion 0.94 vs 4.41 TER per year @ 52wk20 mg
event rate · per year
NCT02792231 · Phase 3
show 6 more results
0.72 vs 3.72 TER per year @ 104wk20 mg
NCT02792231 · Phase 3
0.13 vs 3.84 TER per year20 mg
NCT02792231 · Phase 3
1.13 vs 4.3 TER per year @ 52wk20 mg
NCT02792218 · Phase 3
0.72 vs 3.21 TER per year @ 104wk20 mg
NCT02792218 · Phase 3
0.05 vs 3.73 TER per year20 mg
NCT02792218 · Phase 3
3.7344 vs 13.1533 placebo per year @ 24wk20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
Annualized New or Enlarging T2 Lesion 0.64 vs 4.16 TER per year20 mg
event rate · per year
EOS n=448,442
NCT02792231 · Phase 3
Brain Volume Loss -0.29% (n=437) vs -0.35% (n=433) TER20 mg
percent change · % of baseline
NCT02792231 · Phase 3
show 1 more result
-0.28% (n=418) vs -0.35% (n=408) TER20 mg
NCT02792218 · Phase 3
Relapsed Subjects 16.51% (n=469) vs 32.68% (n=470) TER20 mg
responder rate · % of participants
NCT02792231 · Phase 3
SDMT Impairment 14.3% (n=930) vs 13.7% (n=917) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 3 more results
15.4% (n=930) vs 14% (n=917) TER @ 104wk20 mg
NCT02792231 · Phase 3
14.3% (n=930) vs 13.7% (n=917) TER @ 78wk20 mg
NCT02792218 · Phase 3
15.4% (n=930) vs 12.4% (n=917) TER @ 104wk20 mg
NCT02792218 · Phase 3
Clinical Worsening 20.5% (n=941) vs 21.7% (n=930) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 3 more results
21.4% (n=941) vs 22.6% (n=930) TER @ 104wk20 mg
NCT02792231 · Phase 3
20.5% (n=941) vs 21.7% (n=930) TER @ 78wk20 mg
NCT02792218 · Phase 3
21.4% (n=941) vs 22.6% (n=930) TER @ 104wk20 mg
NCT02792218 · Phase 3
SDMT 1.02 vs 0.64 TER score @ 26wk20 mg
absolute change · score
NCT02792231 · Phase 3
show 9 more results
1.82 vs 1.7 TER score @ 52wk20 mg
NCT02792231 · Phase 3
2.84 vs 2.05 TER score @ 78wk20 mg
NCT02792231 · Phase 3
3.5 vs 2.39 TER score @ 104wk20 mg
NCT02792231 · Phase 3
3.53 vs 2.97 TER score @ 130wk20 mg
NCT02792231 · Phase 3
1.02 vs 0.64 TER score @ 26wk20 mg
NCT02792218 · Phase 3
1.82 vs 1.7 TER score @ 52wk20 mg
NCT02792218 · Phase 3
2.84 vs 2.05 TER score @ 78wk20 mg
NCT02792218 · Phase 3
3.5 vs 2.39 TER score @ 104wk20 mg
NCT02792218 · Phase 3
2.97 vs 2.97 TER score @ 130wk20 mg
NCT02792218 · Phase 3
T25FW 20% Worsening 11% (n=936) vs 10.4% (n=925) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 3 more results
11.4% (n=936) vs 10.6% (n=925) TER @ 104wk20 mg
NCT02792231 · Phase 3
11% (n=936) vs 10.4% (n=925) TER @ 78wk20 mg
NCT02792218 · Phase 3
11.4% (n=936) vs 10.6% (n=925) TER @ 104wk20 mg
NCT02792218 · Phase 3
9HPT 20% Worsening 2.9% (n=932) vs 3.3% (n=920) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 3 more results
2.9% (n=932) vs 3.3% (n=920) TER @ 104wk20 mg
NCT02792231 · Phase 3
2.9% (n=932) vs 3.3% (n=920) TER @ 78wk20 mg
NCT02792218 · Phase 3
2.9% (n=932) vs 3.3% (n=920) TER @ 104wk20 mg
NCT02792218 · Phase 3

+ 19 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ocrelizumab's landscape · Ofatumumab's landscape